$NTLA
Intellia Therapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022007805 Filed on May 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $11.25M $6.445M
YoY Change 74.58% -50.1%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $22.40M $13.59M
YoY Change 64.85% 20.16%
% of Gross Profit
Research & Development $133.1M $39.28M
YoY Change 238.87% 13.35%
% of Gross Profit
Depreciation & Amortization $1.754M $1.591M
YoY Change 10.25% 3.24%
% of Gross Profit
Operating Expenses $133.1M $39.28M
YoY Change 238.87% 13.35%
Operating Profit -$144.2M -$46.43M
YoY Change 210.71% 40.48%
Interest Expense -$2.205M $220.0K
YoY Change -1102.27% -82.26%
% of Operating Profit
Other Income/Expense, Net -$2.626M $220.0K
YoY Change -1293.64%
Pretax Income -$146.9M -$46.21M
YoY Change 217.84% 45.27%
Income Tax
% Of Pretax Income
Net Earnings -$146.9M -$46.21M
YoY Change 217.87% 45.27%
Net Earnings / Revenue -1305.3% -716.91%
Basic Earnings Per Share -$1.96
Diluted Earnings Per Share -$1.965M -$687.9K
COMMON SHARES
Basic Shares Outstanding 74.67M 67.73M
Diluted Shares Outstanding 74.75M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $855.3M $584.1M
YoY Change 46.42% 133.36%
Cash & Equivalents $133.4M $141.5M
Short-Term Investments $721.9M $442.5M
Other Short-Term Assets $18.32M $16.10M
YoY Change 13.76% 163.93%
Inventory
Prepaid Expenses
Receivables $1.801M $953.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $875.4M $601.1M
YoY Change 45.63% 122.79%
LONG-TERM ASSETS
Property, Plant & Equipment $23.70M $94.10M
YoY Change -74.82% 122.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $52.27M $16.70M
YoY Change 213.01%
Other Assets $35.49M $5.000M
YoY Change 609.86% 78.57%
Total Long-Term Assets $327.4M $115.8M
YoY Change 182.75% 157.33%
TOTAL ASSETS
Total Short-Term Assets $875.4M $601.1M
Total Long-Term Assets $327.4M $115.8M
Total Assets $1.203B $716.9M
YoY Change 67.78% 127.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.14M $8.700M
YoY Change 16.53% 123.08%
Accrued Expenses $42.88M $21.22M
YoY Change 102.1% 61.92%
Deferred Revenue $63.76M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $126.1M $60.70M
YoY Change 107.76% 71.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.96M $110.3M
YoY Change -90.06% 247.95%
Total Long-Term Liabilities $10.96M $110.3M
YoY Change -90.06% 247.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $126.1M $60.70M
Total Long-Term Liabilities $10.96M $110.3M
Total Liabilities $137.1M $171.0M
YoY Change -19.84% 155.22%
SHAREHOLDERS EQUITY
Retained Earnings -$849.9M
YoY Change
Common Stock $1.812B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $953.8M $545.9M
YoY Change
Total Liabilities & Shareholders Equity $1.203B $716.9M
YoY Change 67.78% 127.77%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$146.9M -$46.21M
YoY Change 217.87% 45.27%
Depreciation, Depletion And Amortization $1.754M $1.591M
YoY Change 10.25% 3.24%
Cash From Operating Activities -$79.80M -$52.38M
YoY Change 52.36% 35.88%
INVESTING ACTIVITIES
Capital Expenditures $1.429M $2.412M
YoY Change -40.75% 185.44%
Acquisitions $287.0K
YoY Change
Other Investing Activities $48.90M -$23.13M
YoY Change -311.42% -139.68%
Cash From Investing Activities $47.47M -$25.54M
YoY Change -285.86% -144.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $38.89M $45.26M
YoY Change -14.08% 899.45%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 47.32M 58.60M
YoY Change -19.24% 1104.67%
NET CHANGE
Cash From Operating Activities -79.80M -52.38M
Cash From Investing Activities 47.47M -25.54M
Cash From Financing Activities 47.32M 58.60M
Net Change In Cash 14.99M -19.32M
YoY Change -177.59% -181.3%
FREE CASH FLOW
Cash From Operating Activities -$79.80M -$52.38M
Capital Expenditures $1.429M $2.412M
Free Cash Flow -$81.23M -$54.79M
YoY Change 48.26% 39.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001652130
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-37766
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
INTELLIA THERAPEUTICS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-4785571
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
40 Erie Street
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 130
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2022Q1 dei City Area Code
CityAreaCode
857
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
285-6200
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021Q4 us-gaap Assets Current
AssetsCurrent
769303000
CY2022Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
139486000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
337361000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23697000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20968000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
76473000
CY2022Q1 dei Trading Symbol
TradingSymbol
NTLA
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
75853870
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133382000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
123406000
CY2022Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
721869000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
625282000
CY2022Q1 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
0
CY2021Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
100000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1801000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2031000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18315000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18584000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
875367000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
79143000
CY2022Q1 us-gaap Equity Method Investments
EquityMethodInvestments
52272000
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
58131000
CY2022Q1 ntla Investments And Other Assets From Related Parties Current
InvestmentsAndOtherAssetsFromRelatedPartiesCurrent
10000.0
CY2021Q4 ntla Investments And Other Assets From Related Parties Current
InvestmentsAndOtherAssetsFromRelatedPartiesCurrent
10000.0
CY2022Q1 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
35493000
CY2021Q4 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
29558000
CY2022Q1 us-gaap Assets
Assets
1202788000
CY2021Q4 us-gaap Assets
Assets
1294464000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
10138000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9653000
CY2022Q1 ntla Accrued Expenses From Related Party
AccruedExpensesFromRelatedParty
200000
CY2021Q4 ntla Accrued Expenses From Related Party
AccruedExpensesFromRelatedParty
0
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42876000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
43309000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9338000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9112000
CY2022Q1 ntla Contract With Customer Liability Related Party Current
ContractWithCustomerLiabilityRelatedPartyCurrent
41200000
CY2021Q4 ntla Contract With Customer Liability Related Party Current
ContractWithCustomerLiabilityRelatedPartyCurrent
41200000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
63759000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
63759000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
126111000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
125833000
CY2022Q1 ntla Contract With Customer Liability Related Party Noncurrent
ContractWithCustomerLiabilityRelatedPartyNoncurrent
11400000
CY2021Q4 ntla Contract With Customer Liability Related Party Noncurrent
ContractWithCustomerLiabilityRelatedPartyNoncurrent
19900000
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
49481000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
63476000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
62480000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
64911000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10962000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75624167
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75624167
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74485883
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74485883
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1811681000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1745870000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8062000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2632000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-849873000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-703001000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
953754000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1040244000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1202788000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1294464000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11252000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6445000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
133095000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39276000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22403000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13594000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
155498000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
52870000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-144246000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-46425000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
540000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
220000
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2745000
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
421000
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2626000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
220000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-146872000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-46205000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.96
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
74751000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67183000
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-5128000
CY2021Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-13000
CY2022Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
-302000
CY2021Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
0
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-152302000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46218000
CY2022Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
5384000
CY2021Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-146872000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-46205000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1754000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1591000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
18491000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6424000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2426000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1209000
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2745000
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0
CY2022Q1 us-gaap Equity Method Investment Sold Carrying Amount
EquityMethodInvestmentSoldCarryingAmount
2812000
CY2021Q1 us-gaap Equity Method Investment Sold Carrying Amount
EquityMethodInvestmentSoldCarryingAmount
0
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
421000
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2022Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
55990000
CY2021Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-230000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1177000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-422000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5448000
CY2022Q1 ntla Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
-2671000
CY2021Q1 ntla Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
-1596000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
918000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
255000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-57000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-917000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3717000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4588000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-13995000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-5558000
CY2022Q1 ntla Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2204000
CY2021Q1 ntla Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1402000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-79801000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52376000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1429000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2412000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
148330000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
93734000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
125200000
CY2022Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
287000
CY2021Q1 ntla Right Of Use Assets Acquired Under Operating Lease
RightOfUseAssetsAcquiredUnderOperatingLease
40394000
CY2022Q1 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
10541000
CY2021Q1 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
0
CY2022Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
44832000
CY2021Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
47473000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25542000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
38885000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
45255000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8435000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13340000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
47320000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58595000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14992000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-19323000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
125486000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
164606000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
140478000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
145283000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133382000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141538000
CY2022Q1 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
7096000
CY2021Q1 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
3745000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
140478000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
145283000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3721000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
901000
CY2022Q1 ntla Right Of Use Assets Acquired Under Operating Lease
RightOfUseAssetsAcquiredUnderOperatingLease
0
CY2022Q1 ntla Research Milestone Payments
ResearchMilestonePayments
25000000.0
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
868608000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7253000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
861355000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
964768000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2125000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
962643000
CY2022Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2021 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2022Q1 ntla Available For Sales Securities Noncurrent Maturing Beyond Year Five
AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive
0
CY2021Q4 ntla Available For Sales Securities Noncurrent Maturing Beyond Year Five
AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
10541000
CY2022Q1 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
421000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
10962000
CY2022Q1 ntla Discount Rate
DiscountRate
0.07
CY2022Q1 ntla Discount Rate
DiscountRate
0.08
CY2022Q1 ntla Probability Of Achievement
ProbabilityOfAchievement
0.50
CY2022Q1 ntla Probability Of Achievement
ProbabilityOfAchievement
0.50
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6667000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2871000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42876000
CY2022Q1 ntla Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
21376000
CY2021Q4 ntla Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
16979000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11150000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
20359000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3683000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3100000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
43309000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2031000
CY2022Q1 ntla Increase In Accounts Receivables
IncreaseInAccountsReceivables
1801000
CY2022Q1 ntla Decrease In Accounts Receivables
DecreaseInAccountsReceivables
-2031000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1801000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
127235000
CY2022Q1 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-13995000
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
113240000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2130000
CY2021Q1 ntla Increase In Accounts Receivables
IncreaseInAccountsReceivables
953000
CY2021Q1 ntla Decrease In Accounts Receivables
DecreaseInAccountsReceivables
-2130000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
953000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
73931000
CY2021Q1 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-5558000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
68373000
CY2022Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
11183000
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
5558000
CY2022Q1 us-gaap Capitalized Contract Cost Gross
CapitalizedContractCostGross
0
CY2022Q1 us-gaap Investments In And Advances To Affiliates At Fair Value Gross Reductions
InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossReductions
3000000.0
CY2022Q1 ntla Business Combination Upfront Cash Consideration
BusinessCombinationUpfrontCashConsideration
43730000
CY2022Q1 ntla Business Combination Research Contingent Consideration Liabilities
BusinessCombinationResearchContingentConsiderationLiabilities
10541000
CY2022Q1 ntla Business Acquisition Cost Of Acquired Entity Transaction Cost
BusinessAcquisitionCostOfAcquiredEntityTransactionCost
1838000
CY2022Q1 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
56109000
CY2022Q1 ntla Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment
55990000
CY2022Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
287000
CY2022Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
153000
CY2022Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
321000
CY2022Q1 ntla Business Combination Transaction Price
BusinessCombinationTransactionPrice
56109000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18491000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6424000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
453026
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
71.03
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
997703
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
83.64
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
54666
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
57.71
CY2022Q1 ntla Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
35532
CY2022Q1 ntla Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue
71.63
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1360531
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
80.80
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
83.64
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
57.71
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
63.67
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
36.64
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
29800000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
54800000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.016
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.759
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.720
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6305156
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
43.57
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
319680
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
95.90
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
503830
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
16.74
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
181651
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
48.84
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5939355
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
48.50
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
204869000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2431823
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
23.79
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
132300000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-146872000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-46205000
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
74751000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67183000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.96
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7300000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7922000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1040244000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8435000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18491000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-5430000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-146872000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
953754000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
527072000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13340000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6424000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-13000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-46205000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
545873000

Files In Submission

Name View Source Status
0000950170-22-007805-index-headers.html Edgar Link pending
0000950170-22-007805-index.html Edgar Link pending
0000950170-22-007805.txt Edgar Link pending
0000950170-22-007805-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ntla-20220331.htm Edgar Link pending
ntla-20220331.xsd Edgar Link pending
ntla-20220331_cal.xml Edgar Link unprocessable
ntla-20220331_def.xml Edgar Link unprocessable
ntla-20220331_htm.xml Edgar Link completed
ntla-20220331_lab.xml Edgar Link unprocessable
ntla-20220331_pre.xml Edgar Link unprocessable
ntla-ex10_3.htm Edgar Link pending
ntla-ex10_4.htm Edgar Link pending
ntla-ex31_1.htm Edgar Link pending
ntla-ex31_2.htm Edgar Link pending
ntla-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending